Mesenchymal Stem Cell Therapy for Liver Disease: Full of Chances and Challenges

Mesenchymal stem cell (MSC) therapy was explored as a promising alternative to liver transplantation for end-stage liver disease, addressing issues like organ shortages and high costs. The document reviewed 22 completed and several ongoing clinical trials, highlighting MSCs' potential to improve liver function in conditions such as viral-related and alcoholic cirrhosis. However, the effectiveness varied depending on the cause of cirrhosis, and long-term benefits remained unclear. Challenges included determining suitable liver disease types for MSC application, standardizing MSC preparation, and establishing optimal dosing strategies. Despite some positive outcomes, further research and larger controlled trials were needed to enhance safety, efficacy, and clinical application.